oxytetracycline--anhydrous and Chronic-Disease

Postparturient endometritis in cattle is discussed in this review paper, considerable attention being paid to diagnosis and treatment. Clinical examination is stressed in the discussion of diagnosis. The diagnosis of endometritis may be established by rectal and vaginoscopical examination in nearly every case. Cytological and bacteriological examinations supply only little information. In view of the method of treatment, it is essential to determine whether or not the cow is affected with pyometra. Treatment of acute postparturient endometritis consists in intra-uterine administration of oxytetracycline (for a period of from one to three days). Pyometra should be treated by injection of prostaglandins (PG). When it is doubted whether pyometra is developing and a corpus luteum is present, treatment is nevertheless advisable. All other cases of chronic endometritis do not require therapy. The tendency to spontaneous recovery is so considerable in cattle that treatment cannot add anything to the results.

Topics: Acute Disease; Animals; Cattle; Cattle Diseases; Chronic Disease; Endometritis; Female; Instillation, Drug; Oxytetracycline; Pregnancy; Puerperal Infection; Uterus

Topics: Ampicillin; Aniline Compounds; Bronchitis; Chronic Disease; Expectorants; Humans; Oxytetracycline; Penicillinase; Sputum; Toluene

No clinical trials have been conducted in India on the efficacy of parenteral antibacterials to treat footrot in sheep. In addition, there are no studies worldwide on the efficacy of parenteral antibacterials to treat chronic footrot. Sixty two sheep with acute footrot and 30 sheep with chronic footrot from 7 villages in Kashmir, India were recruited into two separate trials. Sheep with acute footrot were allocated to one of three treatments using stratified random sampling: long acting parenteral oxytetracycline, long acting parenteral enrofloxacin and topical application of potassium permanganate solution (a traditional treatment used by sheep farmers in India). In a quasi pre-post intervention design, sheep with chronic footrot that had not responded to treatment with potassium permanaganate were randomly allocated to treatment with one of the two parenteral antibacterials mentioned above. Sheep with acute footrot were treated on day 0 and those with chronic footrot on days 0, 3, 6 and 9. Sheep were monitored for up to 28 days after treatment. Time to recovery from lameness and initial healing of lesions was assessed using Kaplan-Meier survival curves, nonparametric log-rank and Wilcoxon sign-rank tests.. There was significant correlation in recovery from lameness and presence of healing lesions in sheep with acute (r = 0.94) or chronic (r = 0.98) footrot. Sheep with acute footrot which were treated with parenteral antibacterials had a significantly more rapid recovery from lameness and had healing lesions (median = 7 days) compared with those treated with topical potassium permanganate solution (less than 50% recovered in 28 days). The median time to recovery in sheep with chronic footrot treated with either antibacterial was 17 days; this was significantly lower than the median of 75 days lame before treatment with antibacterials. The median time to recovery for both acute and chronic footrot increased as the severity of lesions increased. There was no difference in time to recovery by age, body condition score, duration lame, or presence of pus in the foot within acute and chronically affected sheep.. We conclude that use of parenteral antibacterials to treat sheep lame with either acute or chronic footrot in India is highly effective. This is likely to improve welfare and give economic benefits to the farmers.

Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Infections; Chronic Disease; Delayed-Action Preparations; Enrofloxacin; Female; Fluoroquinolones; Foot Diseases; India; Lameness, Animal; Male; Oxytetracycline; Potassium Permanganate; Sheep; Sheep Diseases

A prospective, randomised, double blind, partial crossover, placebo controlled trial has been conducted to compare the performance of topical fusidic acid gel (Fucithalmic) and oral oxytetracycline as treatment for symptomatic chronic blepharitis. Treatment success was judged both by a reduction in symptoms and clinical examination before and after therapy. Seventy five per cent of patients with blepharitis and associated rosacea were symptomatically improved by fusidic acid gel and 50% by oxytetracycline, but fewer (35%) appeared to benefit from the combination. Patients with chronic blepharitis of other aetiologies did not respond to fusidic acid gel but 25% did benefit from oxytetracycline and 30% from the combination. Our results demonstrate the need to investigate patients with blepharitis for concomitant rosacea as they respond well to targeted therapy.

Topics: Blepharitis; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fusidic Acid; Humans; Male; Middle Aged; Oxytetracycline; Prospective Studies; Rosacea

Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials as Topic; Dexamethasone; Drug Combinations; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nystatin; Otitis; Oxytetracycline; Polymyxin B; Polymyxins

Bromhexine, 16 mg. 3-times daily, was compared with placebo in a double-blind crossover trial in 41 out-patients with chronic bronchitis and irreversible airways obstruction, and who were considered to be in a steady state. Each treatment was given for 3 weeks with a week of placebo in between; in addition, all patients took oxytetracycline, 500 mg. twice daily, starting 1 week before the trial and continuing throughout the duration of it. All patients completed the trial but the results from 5 were excluded because during the first 3 weeks they developed an influenza-like illness accompanied by a decrease in FEV1,and peak expiratory flow rate. Results from the remaining 36 patients showed a statistically significant reduction in phlegm stickiness (p smaller than 0.05) as judged by the patient, and a significant improvement in overall clinical state (p smaller than 0.05) as judged by the physician during bromhexine treatment, but no significant change in symptoms like cough, chest tightness, ease of breathing or sputum volume, peak expiratory flow rate and FEV1 etc. Five patients reported 6 side-effects, 3 with bromhexine, 1 with placebo and 1 with both treatments.

Topics: Adult; Aged; Bromhexine; Bronchitis; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Humans; Influenza, Human; Male; Middle Aged; Oxytetracycline; Pulmonary Ventilation; Respiration; Respiratory Function Tests

Topics: Adult; Amines; Bronchitis; Chronic Disease; Clinical Trials as Topic; Diarrhea; Dyspnea; Female; Humans; Male; Oxytetracycline; Penicillin G; Penicillins; Sputum

Topics: Acute Disease; Bronchitis; Cephalosporins; Chronic Disease; Clinical Trials as Topic; Humans; Oxytetracycline

Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bronchitis; Cephalexin; Chronic Disease; Clinical Trials as Topic; Family Practice; Female; Humans; Male; Middle Aged; Oxytetracycline; Smoking; Sputum; Surveys and Questionnaires; Time Factors

Topics: Acute Disease; Adolescent; Adult; Aged; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Middle Aged; Oxytetracycline

Topics: Aged; Bronchitis; Chronic Disease; Doxycycline; Humans; Middle Aged; Oxytetracycline; Urea

Topics: Adult; Aniline Compounds; Bronchitis; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Expectorants; Female; Humans; Lung Abscess; Male; Middle Aged; Oxytetracycline; Sputum; Toluene

Topics: Aged; Bronchitis; Chronic Disease; Clinical Trials as Topic; Doxycycline; Eczema; Female; Humans; Male; Middle Aged; Oxytetracycline

Topics: Adult; Bronchitis; Chloramphenicol; Chronic Disease; Follow-Up Studies; Haemophilus influenzae; Humans; Male; Middle Aged; Oxytetracycline; Proteus; Sputum; Streptococcus pneumoniae; Sulfonamides

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis; Child; Child, Preschool; Chloramphenicol; Chronic Disease; Drug Resistance, Microbial; Expectorants; Female; Humans; Male; Middle Aged; Oxytetracycline; Sputum; Sulfonamides; Tetracycline

Chronic, non-healing wounds are often characterised by an excessive, and detrimental, inflammatory response. We review our experience of using a combined topical steroid, antibiotic and antifungal preparation in the treatment of chronic wounds displaying abnormal and excessive inflammation.. A retrospective review was undertaken of all patients being treated with a topical preparation containing a steroid (clobetasone butyrate 0.05%), antibiotic and antifungal at a tertiary wound healing centre over a ten-year period. Patients were selected as the primary treating physician felt the wounds were displaying excessive inflammation. Healing rates were calculated for before and during this treatment period for each patient. Changes in symptom burden (pain, odour and exudate levels) following topical application were also calculated.. Overall, 34 ulcers were identified from 25 individual patients (mean age: 65 years, range: 37-97 years) and 331 clinic visits were analysed, spanning a total time of 14,670 days (7,721 days 'before treatment' time, 6,949 days 'during treatment' time). Following treatment, 24 ulcers demonstrated faster rates of healing, 3 ulcers showed no significant change in healing rates and 7 were healing more slowly (p=0.0006). Treatment generally reduced the burden of pain and exudate, without affecting odour.. In normal wound healing, inflammation represents a transient but essential phase of tissue repair. In selected cases, direct application of a steroid containing agent has been shown to improve healing rates, presumably by curtailing this phase. Further evaluation is required to establish the role of preparations containing topical steroids without antimicrobials in the management of chronic wounds.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Chronic Disease; Clobetasol; Drug Combinations; Female; Glucocorticoids; Humans; Inflammation; Male; Middle Aged; Nystatin; Ointments; Oxytetracycline; Retrospective Studies; Wound Healing

Synoviorthesis is already widely used in the treatment of chronic haemophilic synovitis. The aim of this study was evaluate the effectiveness of oxytetracicline synoviorthesis on the frequency of haemarthrosis in haemophilic children with chronic synovitis and its impact on joint function. Between January 2001 and October 2006, we performed 34 synoviorthesis in 28 paediatric patients (6-16 years old) with diagnosis of haemophilic arthropathy stage I-II. At each joint were administered five doses of oxytetracycline for five consecutive weeks at doses of 100 mg in elbow and ankle and 250 mg in the knee. The frequency of haemarthrosis and range of joint mobility were evaluated before and after of treatment. The results were analysed with Student t-test and descriptive statistics. Thirty-four joints were treated, including 20 knees (58.8%), eight elbows (23.5%) and six ankles (17.6%). Median follow-up was 46.3 months (range 12-71 months). The frequency of haemarthrosis was recorded before treatment 47.3 year(-1) (range 12-96, P < 0.0001) and decreased to 3.5 year(-1) (range 0-15, P = 0.0119) after treatment. The range of joint motion in flexion-extension before treatment was 84.9°, while after this was 97.5° (P = 0.0119). The synoviorthesis with oxytetracycline has shown a favourable effect in the treatment of chronic haemophilic synovitis in reducing the frequency of haemarthrosis and improvement was observed consistently in the range of motion.

Topics: Adolescent; Adult; Ankle Joint; Anti-Bacterial Agents; Child; Chronic Disease; Elbow Joint; Follow-Up Studies; Hemarthrosis; Hemophilia A; Humans; Injections, Intra-Articular; Knee Joint; Oxytetracycline; Range of Motion, Articular; Synovitis; Young Adult

Chronic infection with Pseudomonas aeruginosa is common in cystic fibrosis (CF) and certain strains are more transmissible and virulent than others. Of these, the Liverpool Epidemic Strain (LES) is highly transmissible and cross infection has been reported between patients with CF and healthy non-CF relatives. However, the risk of transmission from humans to animals is unknown. The first report of interspecies transmission of the LES strain of P aeruginosa from an adult patient with CF to a pet cat is described. This development further complicates the issue of infection control policies required to prevent the spread of this organism.

Topics: Animals; Animals, Domestic; Anti-Bacterial Agents; Cat Diseases; Cats; Chronic Disease; Cystic Fibrosis; Humans; Male; Middle Aged; Oxytetracycline; Pseudomonas aeruginosa; Pseudomonas Infections

Topics: Anemia; Animals; Anti-Bacterial Agents; Chronic Disease; Female; Immunohistochemistry; Lymph Nodes; Mycoplasma Infections; Oxytetracycline; Sheep; Sheep Diseases; Treatment Outcome

A field trial was performed under commercial feedlot conditions in western Canada to compare the efficacy of a new formulation of long-acting oxytetracycline (LA 30) to a standard long-acting oxytetracycline formulation (LA 20) and florfenicol (FLOR) for the treatment of undifferentiated fever (UF) in calves that received metaphylactic tilmicosin upon arrival at the feed-lot. Seven hundred and ninety-seven recently weaned, auction market derived, crossbred, beef calves suffering from UF were allocated to 1 of 3 experimental groups as follows: LA 30, which received intramuscular long-acting oxytetracycline (300 mg/mL formulation) at the rate of 30 mg/kg body weight (BW) at the time of allocation; LA 20, which received intramuscular long-acting oxytetracycline (200 mg/mL formulation) at the rate of 20 mg/kg BW at the time of allocation; or FLOR, which received intramuscular florfenicol administered at the rate of 20 mg/kg BW at the time of allocation and again 48 hours later. Two hundred and sixty-six animals were allocated to the LA 30 group, 265 animals were allocated to the LA 20 group, and 266 animals were allocated to the FLOR group. The relative efficacy of the LA 30 group, as compared with the LA 20 and FLOR groups, was assessed by comparing relapse, chronicity, wastage, and mortality rates. The overall mortality (RR = 0.50) rate in the LA 30 group was significantly (P < 0.05) lower than in the LA 20 group. However, the overall chronicity (RR = 2.56) and overall wastage (RR = 6.97) rates of the LA 30 group were significantly (P < 0.05) higher than in the LA 20 group. There were no significant (P > or = 0.05) differences in UF relapse rates or cause specific mortality rates between the LA 30 and LA 20 groups. In the economic analysis, there was an advantage of $28.59 CDN per animal in the LA 30 group compared with the LA 20 group. The overall chronicity (RR = 2.25) and overall wastage (RR = 2.80) rates of the LA 30 group were significantly (P < 0.05) higher than the FLOR group. There were no significant (P > or = 0.05) differences in UF relapse rates, overall mortality rates, or cause specific mortality rates between the LA 30 and FLOR groups. In the economic analysis, there was an advantage of $12.90 CDN per animal in the LA 30 group compared with the FLOR group. In summary, the results of this study indicate that it is more cost-effective to use a new formulation of long-acting oxytetracycline (300 mg/mL formulation administered at a rate of 30 mg/k

Topics: Animals; Anti-Bacterial Agents; Canada; Cattle; Cattle Diseases; Chronic Disease; Cost-Benefit Analysis; Fever; Injections, Intramuscular; Oxytetracycline; Random Allocation; Recurrence; Thiamphenicol; Treatment Outcome; Weight Loss

The combined effects of the uterine infusion of EDTA-Tris solution and antibiotics have been evaluated in 75 cases of slight, moderate or severe bovine endometritis which did not respond to local routine antimicrobial therapy. Antibiotic-resistant bacteria were isolated from uterine swabs. The cows were divided into three groups on the basis of the severity of endometritis and treated with 100 ml of sterile EDTA-Tris solution (250 mM EDTA and 50 mM tris, pH 8) and the same antibiotic used in the first unsuccessful treatment (oxytetracycline, enrofloxacin, lincomycin-spectinomycin or amikacin). Control groups consisting of six animals treated with antibiotic alone were used. Clinical evaluations performed 2, 15, 21, 42 and 63 days after treatment revealed good therapeutic results, as 53 cows showed a complete recovery with renormalization of the subsequent oestrus cycle. Artificial insemination was followed by pregnancy in about 90% of treated cows. In control animals the second treatment performed using only the antibiotic gave variable and unsatisfactory results, particularly in animals affected by severe endometritis.

Topics: Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cattle; Cattle Diseases; Chronic Disease; Drug Resistance, Microbial; Edetic Acid; Endometritis; Enrofloxacin; Female; Fluoroquinolones; Instillation, Drug; Lincomycin; Oxytetracycline; Quinolones; Solutions; Spectinomycin; Tromethamine; Uterus

The article analyses the immediate and late-term results of treatment of patients suffering from thromboangiitis of the lower limbs with acute forms of thromboses of the main arteries and shunts (13 persons) and chronic arterial insufficiency (60 patients). The treatment consisted in intraarterial drug infusion with the use of fibrinolysis activators (celiasa, awelysin) as well as other pathogenetically aimed agents in the form of microcrystal suspensions (hydrocortisone, oxytetracycline, zinc insulin). Regional thrombolysis in acute thrombosis allowed authentic lysis of fresh thrombi in the main arteries in two patients (15%). Local thrombolysis with subsequent course of arterial infusion made possible effective arrest of the local ischemic syndrome in patients with III-IV degree arterial insufficiency and affection of the distal arterial bed and allowed the limb to be preserved during a follow-up period of 2 years in 92.5% of patients.

Topics: Acute Disease; Adult; Chronic Disease; Femoral Artery; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydrocortisone; Infusions, Intra-Arterial; Ischemia; Leg; Male; Middle Aged; Oxytetracycline; Streptokinase; Thromboangiitis Obliterans; Thrombolytic Therapy; Thrombosis; Zinc

We compared the clinical efficacy of Auricularum to its bacteriological efficacy in 36 patients with a chronic middle ear disease. The clinical study confirms the very good efficacy of Auricularum with an improvement rate equal to 81% and 69.4% of "very good" results. The bacteriological study confirms the usual sensitivity of gram-negative bacilli (except the Proteus) to polymyxine B, the sensitivity of gram-positive germs to tetracycline for 60% of them and the sensitivity of fungus (isolated only once) to nystatine. Moreover, the bacteriological study shows that Auricularum with a concentration more or equal to 0.1 ml inhibits every germ, including the well-known resistant germs. This concentration of 0.1 ml corresponds to 2 drops of the drug in suspension and is less than the recommended dosage. This finding proves the very good efficacy of Auricularum in chronic middle ear diseases, including the ones due to usual resistant germs to the two antibiotics (polymyxine B and oxytetracycline) enclosed in the drug composition.

Topics: Bacteriological Techniques; Chronic Disease; Dexamethasone; Drug Combinations; Humans; Microbial Sensitivity Tests; Nystatin; Otitis Media; Oxytetracycline; Polymyxin B; Polymyxins

The remote results of combined therapy of 300 patients with chronic pyoderma were estimated by the data of the 5-year catamneses. The patients were treated with the use of erycycline, a combined drug consisting of two antibiotics made in the USSR. Stable clinical recovery within 5 years was stated in 78.8 per cent of the patients. Significant improvement (single pustules 2-3 years after discontinuation of the treatment) was registered in 13.7 per cent of the patients. Improvement (insignificant relapses within the first 2 years) was stated in 6.3 per cent of the patients. No effect of the combined therapy was stated in 1.2 per cent of the patients. It was shown that the use of erycycline in the combined therapy of the patients with chronic pyoderma provided its high efficacy, favourable immediate and remote results, decreasing the treatment period at the average by 3.8 days and decreasing the number of relapses. It also provided economy. The analysis of the catamneses promoted critical and objective estimation of the treatment results and stability of the therapeutic remission thus facilitating solution of the problem of treatment and prophylaxis of chronic pyoderma.

Topics: Adolescent; Adult; Chronic Disease; Combined Modality Therapy; Drug Combinations; Erythromycin; Female; Humans; Male; Middle Aged; Oxytetracycline; Pyoderma; Staphylococcal Skin Infections; Staphylococcal Toxoid

Topics: Adolescent; Adult; Chronic Disease; Combined Modality Therapy; Drug Combinations; Erythromycin; Female; Humans; Leg Ulcer; Levamisole; Oxytetracycline; Pyoderma; Staphylococcal Infections

Topics: Adolescent; Adult; Animals; Bees; Biological Products; Chronic Disease; Clothing; Drug Combinations; Drug Evaluation; Erythromycin; Female; Humans; Male; Middle Aged; Oxytetracycline; Pyoderma; Recurrence; Time Factors

Sixteen cattle serotest-negative for anaplasmosis with either no previous exposure (2 animals) or cleared 8 months earlier of their carrier state by chemotherapy (14 animals) were each exposed to Anaplasma marginale. Anaplasma serotest titers were determined by complement-fixation and rapid card agglutination tests conducted during a 63-day trial period. Serologic reactions indicated that all cattle (both groups) were converted to seropositive by the 21st day after exposure. Fluctuations in PCV were seen in the 2 groups between days 21 and 35. However, parasitemia levels were detectable only in the 2 previously unexposed control cattle. Three splenectomized calves, given 10 ml of blood from 3 of the former carrier cattle 14 days after the latter were reexposed, developed severe clinical and hematologic signs of anaplasmosis and seroconverted from negative to positive on both serologic tests. The need to acquire a better understanding of immunity in anaplasmosis is discussed.

Topics: Anaplasma; Anaplasmosis; Animals; Antibodies, Bacterial; Carrier State; Cattle; Cattle Diseases; Chronic Disease; Female; Male; Oxytetracycline

Topics: Abscess; Adult; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Erythromycin; Female; Folliculitis; Furunculosis; Humans; Male; Middle Aged; Oxytetracycline; Pyoderma; Skin Ulcer; Staphylococcal Infections; Streptococcal Infections

Topics: Adult; Ampicillin; Bronchitis; Chronic Disease; Drug Combinations; Germany, East; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxytetracycline; Sulfamerazine; Trimethoprim

Four injections of a long-acting oxytetracycline (20 mg/kg) were administered at 3-day intervals to 14 naturally infected anaplasmosis carrier cattle. Individual anaplasma serology titers were evaluated, using complement-fixation and rapid card-agglutination tests at frequent intervals during a 180-day posttreatment period. Serologic results indicated fluctuating complement-fixation titers during the trial period. However, at trial termination, 12 of 14 animals were negative by complement-fixation testing and all animals were card-test negative. Eight splenectomized calves given 10 ml of blood from the medicated cows at their posttreatment day 150 failed to manifest any clinical, hematologic, or serologic signs of anaplasmosis during 56 days. Susceptibility to anaplasmosis challenge exposure was demonstrated by positive clinical and serotest reactions when 3 of the recipient calves were inoculated with blood from a parasitemic carrier calf.

Topics: Agglutination Tests; Anaplasma; Anaplasmosis; Animals; Antibodies, Bacterial; Carrier State; Cattle; Cattle Diseases; Chronic Disease; Complement Fixation Tests; Delayed-Action Preparations; Female; Oxytetracycline; Splenectomy

Topics: Amoxicillin; Bronchitis; Chronic Disease; Humans; Male; Oxytetracycline; Sulfamethoxazole; Trimethoprim

Topics: Asthma; Chronic Disease; Doxycycline; Humans; Oxytetracycline; Respiratory Tract Infections

Due to the mainly infectious genesis drug-therapy with antibiotics is essential in chronic non-specific respiratory diseases. But they are only indicated when a bacterial infection is suspected. The broad spectrum antibiotics usually have a reliable efficacy. Bacteriological examination is no obligate supposition. But it is necessary if new drugs with limited effectiveness are intended to be given. In most cases of chronic bronchitis an intermittent application is sufficient. A continuous treatment is indicated only in a few cases. Some details of antibiotic therapy (kind of drugs, dosage, duration of treatment, side-effects etc.) are discussed. The possibility of antibiotic therapy in respiratory virus infections is inquired.

Topics: Ampicillin; Anti-Bacterial Agents; Cephaloridine; Chloramphenicol; Chronic Disease; Erythromycin; Gentamicins; Humans; Lincomycin; Oxacillin; Oxytetracycline; Penicillin Resistance; Respiratory Tract Infections; Trimethoprim

Topics: Ampicillin; Anti-Bacterial Agents; Bronchitis; Cephalosporins; Chloramphenicol; Chronic Disease; Clindamycin; Drug Evaluation; Haemophilus influenzae; Humans; Oxytetracycline; Penicillin Resistance; Streptococcus; Sulfamethazine; Tetracycline; Trimethoprim

Topics: Adolescent; Adult; Aged; Chlortetracycline; Chronic Disease; Climate; Humans; Middle Aged; Oxytetracycline; Penicillins; Phenols; Silver Nitrate; Skin Ulcer; Sulfonamides; Vitamins

Topics: Acute Disease; Adult; Bromhexine; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Oxytetracycline; Sinusitis; Time Factors

Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Bronchial Neoplasms; Bronchoscopy; Chloramphenicol; Chronic Disease; Diagnosis, Differential; Female; Humans; Leukocytosis; Male; Middle Aged; Oxytetracycline; Pneumonia; Radiography; Sex Factors; Time Factors; Tuberculosis, Pulmonary

Topics: Acute Disease; Blood Sedimentation; Bronchial Diseases; Chronic Disease; Doxycycline; Humans; Lung Diseases; Oxytetracycline; Radiography

Topics: Chronic Disease; Female; Gonorrhea; Humans; Neisseria gonorrhoeae; Oxytetracycline; Pregnancy

Topics: Ammonium Chloride; Bronchopneumonia; Chronic Disease; Humans; Oxygen Consumption; Oxytetracycline; Pulmonary Diffusing Capacity; Respiratory Function Tests; Suppuration; Ventilation-Perfusion Ratio; Vital Capacity

Topics: Ampicillin; Anti-Bacterial Agents; Bacteria; Bronchiectasis; Bronchitis; Cephaloridine; Chloramphenicol; Chronic Disease; Cloxacillin; Erythromycin; Humans; Lactose; Methicillin; Oxytetracycline; Penicillin G; Penicillin Resistance; Pneumonia; Pneumonia, Staphylococcal; Pneumonia, Viral; Streptomycin; Tetracycline

Topics: Adult; Aged; Aniline Compounds; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Oxytetracycline; Quaternary Ammonium Compounds; Toluene

Topics: Acute Kidney Injury; Adult; Anuria; Chronic Disease; Diuresis; Female; Glomerulonephritis; Humans; Hypertension, Malignant; Kidney Function Tests; Kinetics; Male; Middle Aged; Nephritis, Interstitial; Nephrosclerosis; Oxytetracycline; Renal Dialysis

Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Chronic Disease; Female; Humans; Oxytetracycline; Phosphates; Prednisone; Pulmonary Fibrosis

Topics: Acetylcysteine; Aniline Compounds; Asthma; Bronchitis; Chronic Disease; Chymotrypsin; Expectorants; Humans; Oxytetracycline; Sputum; Toluene

Topics: Administration, Oral; Adult; Aged; Capreomycin; Chronic Disease; Drug Combinations; Ethambutol; Female; Humans; Kanamycin; Lung; Male; Middle Aged; Mycobacterium tuberculosis; Oxytetracycline; Pyrazinamide; Radiography; Rifampin; Sputum; Time Factors; Tuberculosis, Pulmonary

Topics: Adolescent; Adult; Aged; Bacteriuria; Cephalothin; Chloramphenicol; Chronic Disease; Colistin; Drug Resistance, Microbial; Escherichia coli Infections; Female; Gentamicins; Humans; Kanamycin; Male; Methacycline; Middle Aged; Oxytetracycline; Proteus Infections; Rifampin; Sulfamethoxypyridazine; Urinary Tract Infections

Topics: Acute Disease; Adult; Chloramphenicol; Chlortetracycline; Chronic Disease; Depression, Chemical; Female; Gonorrhea; Humans; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Oxytetracycline; Penicillin Resistance; Penicillins; Streptomycin; Tetracycline

Topics: Adult; Bronchitis; Chronic Disease; Drug Synergism; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Oxytetracycline; Pyrimidines; Sputum; Sulfamethoxazole; Time Factors

Topics: Adolescent; Adult; Aged; Bacteria; Chronic Disease; Female; Humans; Kidney Diseases; Male; Middle Aged; Oxytetracycline; Urinary Tract Infections

Topics: Adult; Aged; Bronchopneumonia; Chronic Disease; Female; Humans; Male; Middle Aged; Oxytetracycline; Quaternary Ammonium Compounds

Topics: Acute Disease; Chronic Disease; Gels; Humans; Hydrocortisone; Maxillary Sinus; Oroantral Fistula; Oxytetracycline; Polymyxins; Postoperative Complications; Sinusitis

Topics: Ampicillin; Animals; Anti-Bacterial Agents; Chronic Disease; Diffusion; Dogs; Erythromycin; Escherichia coli Infections; Humans; Kanamycin; Klebsiella Infections; Male; Middle Aged; Nalidixic Acid; Nitrofurantoin; Oleandomycin; Oxytetracycline; Penicillins; Prostate; Prostatitis; Sulfonamides

Topics: Anti-Bacterial Agents; Bacillus; Bacteria; Chloramphenicol; Chlortetracycline; Chronic Disease; Colistin; Corynebacterium; Depression, Chemical; Erythromycin; Erythromycin Ethylsuccinate; Escherichia coli; Humans; Microbial Sensitivity Tests; Nasal Mucosa; Otitis Media; Oxytetracycline; Penicillin Resistance; Penicillins; Proteus; Pseudomonas aeruginosa; Staphylococcus; Streptomycin; Suppuration; Tetracycline

Topics: Chronic Disease; Dexamethasone; Humans; Natamycin; Otitis Externa; Oxytetracycline; Tetracaine

Topics: Aged; Bronchitis; Bronchodilator Agents; Chronic Disease; Expectorants; Female; Humans; Male; Middle Aged; Oxytetracycline; Sulfadiazine; Time Factors

Topics: Adult; Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Bronchitis; Chronic Disease; Creatinine; Female; Humans; Male; Middle Aged; Oxytetracycline; Spirometry; Transaminases

Topics: Chronic Disease; Gels; Humans; Hydrocortisone; Maxillary Sinus; Oxytetracycline; Sinusitis

Topics: Adolescent; Adult; Age Factors; Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Collapse Therapy; Cycloserine; Ethambutol; Ethionamide; Female; Germany; Humans; Isoniazid; Male; Middle Aged; Oxytetracycline; Pneumonectomy; Streptomycin; Time Factors; Tuberculosis, Pulmonary

Topics: Acute Disease; Adult; Bronchi; Bronchitis; Chronic Disease; Expectorants; Humans; Male; Oxytetracycline; Sulfadiazine

Topics: Aerosols; Bronchitis; Chloramphenicol; Chronic Disease; Humans; Mucus; Oxytetracycline; Penicillins; Respiratory Therapy; Sulfadimethoxine; Sulfonamides

Topics: Arthritis, Infectious; Chlorides; Chronic Disease; Female; Genital Diseases, Female; Humans; Inflammation; Iontophoresis; Oxytetracycline; Staphylococcus

Topics: Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Expectorants; Humans; Oxytetracycline; Quaternary Ammonium Compounds

Topics: Bronchitis; Chronic Disease; Female; Humans; Male; Oxytetracycline; Sputum

Topics: Anti-Bacterial Agents; Bacteria; Bronchitis; Chloramphenicol; Chronic Disease; Enterobacter; Escherichia; Escherichia coli; Haemophilus influenzae; Humans; Oxytetracycline; Penicillin Resistance; Penicillins; Proteus; Pseudomonas; Sputum; Staphylococcus; Streptococcus; Streptococcus pneumoniae; Streptomycin

Topics: Anti-Bacterial Agents; Bronchitis; Chloramphenicol; Chronic Disease; Demeclocycline; Humans; Methacycline; Oxytetracycline; Tetracycline

Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Autoantibodies; Chloramphenicol; Chronic Disease; Eczema; Humans; Immunotherapy; Ointments; Oxytetracycline; Penicillin Resistance; Penicillins; Salicylates; Skin Diseases, Infectious; Staphylococcal Infections; Streptomycin; Tars; Zinc

Topics: Adult; Aged; Aprotinin; Chronic Disease; Female; Humans; Male; Middle Aged; Oxytetracycline; Pancreatitis

Topics: Bronchiectasis; Bronchitis; Chronic Disease; Expectorants; Female; Humans; Male; Oxytetracycline

Topics: Adult; Bronchitis; Chronic Disease; Drug Synergism; Female; Humans; Male; Middle Aged; Oxytetracycline; Quaternary Ammonium Compounds

Topics: Aged; Antitussive Agents; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Oxytetracycline; Respiratory Function Tests; Spirometry

Topics: Amebicides; Chronic Disease; Dysentery; Dysentery, Amebic; Entamoebiasis; Humans; Oxytetracycline

Topics: Bacteria; Bronchiectasis; Chronic Disease; Lung; Oxytetracycline; Pulmonary Emphysema

Topics: Adolescent; Child; Chronic Disease; Humans; Japan; Maxillary Sinus; Nasal Mucosa; Oxytetracycline; Pathology; Peptide Hydrolases; Prednisone; Pronase; Sinusitis

Topics: Chronic Disease; Communicable Diseases; Humans; Oxytetracycline; Respiratory System; Respiratory Tract Infections

Topics: Amebiasis; Chronic Disease; Dysentery, Amebic; Intestines; Oxytetracycline

Topics: Chronic Disease; Otitis Media; Oxytetracycline

Topics: Animals; Birds; Chlortetracycline; Chronic Disease; Disease; Mycoplasma; Oxytetracycline; Poultry; Respiration; Trachea

Topics: Chronic Disease; Oxytetracycline; Urticaria

Topics: Chronic Disease; Communicable Diseases; Humans; Oxytetracycline; Respiratory System; Respiratory Tract Diseases; Respiratory Tract Infections

Topics: Chemical and Drug Induced Liver Injury; Chlortetracycline; Chronic Disease; Fatty Liver; Liver Diseases; Oxytetracycline